PT - JOURNAL ARTICLE AU - Salarifar, Mojtaba AU - Ghavami, Mojgan AU - Poorhosseini, Hamidreza AU - Masoudkabir, Farzad AU - Jenab, Yaser AU - Amirzadegan, Alireza AU - Alidoosti, Mohammad AU - Aghajani, Hassan AU - Bozorgi, Ali AU - Hosseini, Kaveh AU - Lotfi-Tokaldany, Masoumeh AU - Mortazavi, Seyedeh Hamideh AU - Aein, Afsaneh AU - Ahmadian, Tahere AU - Sadeghian, Saeed TI - Management and Outcomes of ST-segment Elevation Myocardial Infarction During Coronavirus 2019 Pandemic in a Center with 24/7 Primary Angioplasty Capability: Should We Change Our Practice During Outbreak? AID - 10.1101/2020.05.02.20088302 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.02.20088302 4099 - http://medrxiv.org/content/early/2020/05/06/2020.05.02.20088302.short 4100 - http://medrxiv.org/content/early/2020/05/06/2020.05.02.20088302.full AB - Background ST-Elevation Myocardial Infarction (STEMI) is associated with high mortality and morbidity. In order to minimize cardiac tissue injury, primary per-cutaneous coronary intervention (PPCI) as treatment of choice should be performed as soon as possible. Coronavirus Disease 2019 (COVID-19) as an ongoing major global concern affects the other parts of health care system. Applying preventive strategies during this outbreak is necessary. However, critical times in STEMI management and outcomes may be influenced by infection control protocols implementation. The aim of this study is to investigate the differences in time intervals related to STEMI care and 15-day major adverse cardiac events (MACE) during this outbreak compared with the same period in last year and to determine whether the STEMI protocol should be changed to thrombolytic therapy during COVID-19 outbreak or not.Methods The patients with STEMI who underwent PPCI in Tehran Heart Center were included. Chest Computed tomography (CT) imaging and real time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) were only performed for COVID-19 suspected patients. Seventy-seven patients from 29th February to 29th March 2020 were compared with 62 patients from 1st to 30th March 2019.Results COVID-19 infection was confirmed by rRT-PCR in 5 cases. CT imaging in 4 out of 5 patients was in favor of COVID-19. The median of door-to-device time was reduced 13 minutes during this outbreak (p: 0.007). In-hospital mortality before and during outbreak was 3.22% and 5.19%, respectively (p: 0.57). Confirmed infection with COVID-19 was only reported in one of expired cases. The difference in 15-day MACE between two time periods was not statistically significant.Discussion/Conclusion Given that 15-day outcome in acute STEMI patients is not affected by COVID-19 outbreak, we did not find it reasonable to change our protocol. However, further studies are needed to determine a standard protocol for emergency management.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIR.TUMS.VCR.REC.1399.023Funding StatementThe authors received no financial support to report.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data are available on an open repository.